GLP-1 RA Exposure After Diagnosis Could Lead to Reduced Progression, Improved Survival in Multiple Malignancies

Overcoming Misinformation Starts With 1 Person at a Time

GLP-1 receptor agonists are already central to conversations around diabetes, weight management, and cardiometabolic health. This ASCO Daily News article connects that timely discussion to oncology by reporting on a large real-world analysis that found associations between GLP-1 RA exposure after cancer diagnosis and reduced metastatic progression across multiple malignancies. The piece also emphasizes the need for randomized trials before the findings can be applied more broadly.